Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages

• Published in: FEBS letters Vol. 512; no. 1; pp. 85 - 90
• Main Authors: Gbaguidi, F.G, Chinetti, G, Milosavljevic, D, Teissier, E, Chapman, J, Olivecrona, G, Fruchart, J.C, Griglio, S, Fruchart-Najib, J, Staels, B
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 13-02-2002
• Subjects: Atherosclerosis; Biological Transport; Cell Differentiation; Diabetes; Humans; Lipoprotein Lipase - metabolism; Lipoprotein metabolism; Lipoproteins, LDL - metabolism; Macrophages - cytology; Macrophages - metabolism; Monocytes - cytology; Monocytes - metabolism; Receptors, Cytoplasmic and Nuclear - agonists; Transcription Factors - agonists; Vascular wall; Diabetes; Lipoprotein metabolism; Vascular wall; Atherosclerosis
• ISSN: 0014-5793; 1873-3468
• DOI: 10.1016/S0014-5793(02)02223-8

Lipoprotein lipase (LPL) acts independently of its function as triglyceride hydrolase by stimulating macrophage binding and uptake of native, oxidized and glycated LDL. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors expressed in monocyte/macrophages, where they control cholesterol homeostasis. Here we study the role of PPARs in the regulation of LPL expression and activity in human monocytes and macrophages. Incubation of human monocytes or macrophages with PPARα or PPARγ ligands increases LPL mRNA and intracellular protein levels. By contrast, PPAR activators decrease secreted LPL mass and enzyme activity in differentiated macrophages. These actions of PPAR activators are associated with a reduced uptake of glycated LDL and could influence atherosclerosis development associated with diabetes.